10-Q: Exagen Inc. Reports Q1 2026 Financial Results

Exagen Inc. reported an 11.7% increase in revenue for the first quarter of 2026, driven by biomarker enhancements and a growing average selling price.

Summary

• Exagen Inc. reported revenue of $17.3 million for the three months ended March 31, 2026, an increase of 11.7% compared to $15.5 million in the same period of 2025.
• The number of AVISE CTD tests delivered increased by approximately 10% year-over-year.
• The average selling price (ASP) for AVISE CTD tests increased by $25 to $444 per test in Q1 2026 from $419 in Q1 2025.
• Gross margin slightly improved to 59.0% from 58.9% year-over-year.
• The company reported a net loss of $4.0 million for the quarter, compared to a net loss of $3.8 million in the prior year period.
• Cash and cash equivalents decreased to $21.5 million as of March 31, 2026, from $32.2 million as of December 31, 2025.
• The company believes its existing capital resources are sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with revenue growth and ASP improvement being positive, but offset by an increased net loss and a significant decrease in cash.

Positives

• Revenue increased by 11.7% to $17.3 million in Q1 2026 compared to Q1 2025.
• Test volume for AVISE CTD increased by approximately 10% in Q1 2026 compared to Q1 2025.
• Average Selling Price (ASP) for AVISE CTD tests increased by 6% to $444 per test in Q1 2026.
• Gross margin improved slightly to 59.0% in Q1 2026 from 58.9% in Q1 2025.
• The company believes its current capital is sufficient for at least the next twelve months.
• The company is developing new biomarkers for Lupus Nephritis (LN) and SLE Disease Activity, with potential for future adoption and commercial release.

Negatives

• Net loss increased to $4.0 million in Q1 2026 from $3.8 million in Q1 2025.
• Cash and cash equivalents decreased significantly from $32.2 million to $21.5 million during the quarter.
• Cost of revenue increased by 11.4% due to higher material and supply costs.
• Selling, general and administrative expenses increased by 7.7%.
• Research and development expenses increased by 21.0%.
• Interest expense increased significantly due to the Perceptive Term Loan Facility and an embedded finance lease.

Risks

• The company has incurred recurring losses and negative cash flows from operating activities since inception and anticipates continuing net losses.
• The company may require additional funding to support operations and growth, and there is no assurance that such financing will be available on acceptable terms.
• Failure to obtain or maintain coverage and adequate reimbursement from third-party payors could hinder revenue growth.
• Changes in estimated reimbursements can positively or negatively impact revenue and cause financial results to fluctuate.
• The company is dependent on key suppliers for certain laboratory materials, and an interruption in supply could impact testing services.
• The current inflationary environment has impacted costs for laboratory testing services, personnel, and other operating costs.
• Uncertainty and changes in U.S. trade policies could adversely affect the business, results of operations, and financial condition.
• The company's ability to achieve sufficient market acceptance, coverage, and reimbursement for its testing products is critical.
• The timing of research and development expenses is difficult to predict and can affect financial results.
• The company's obligations under the Perceptive Term Loan Facility are secured by a first-priority lien on substantially all of its assets.

Future Outlook

The company expects to continue incurring operating losses in the near term. They anticipate increases in cost of revenue due to new biomarkers and increases in selling, general and administrative expenses due to sales force expansion. Research and development expenses are expected to remain relatively consistent in the short-term. The company believes its existing capital and anticipated future revenue will be sufficient to meet cash requirements for at least the next twelve months, but may require additional funding through equity offerings, debt financings, or other capital sources.

Management Comments

• Under the leadership of our Chief Executive Officer, John Aballi, who joined Exagen in October 2022, we have executed an operational turnaround of the business, resulting in a return to revenue growth and gross margin expansion while significantly reducing operating expenses and cash burn.
• We believe our strong focus and extensive background in the field of rheumatology, combined with our commitment to exceptional customer service and support, position us well to respond to the needs of rheumatologists, primary care physicians, other specialists, and the patients they serve.
• We strive to become a partner of choice for doctors, hospitals, healthcare systems, and payors.

Industry Context

StockSavvy.ai notes that Exagen Inc. operates in the competitive diagnostics market, focusing on autoimmune diseases. The company's strategy of enhancing its AVISE CTD platform with new biomarkers and expanding its sales force aligns with industry trends of precision medicine and specialized diagnostic solutions. However, the company faces significant challenges related to reimbursement and the long sales cycles typical in the healthcare sector.

Comparison to Industry Standards

• The company's gross margin of 59.0% is within a reasonable range for diagnostic testing companies, though specific benchmarks vary widely based on test complexity and reimbursement models.
• The reported net loss is common for companies in the development and commercialization phase of specialized medical diagnostics, where significant R&D and sales investments are required before achieving profitability.
• The increase in ASP for AVISE CTD tests by 6% is a positive indicator, suggesting successful market adoption of enhanced product offerings, which is a key strategy for many diagnostic companies seeking to improve per-test revenue.

Legal Proceedings

• The company is not currently party to any material legal proceedings.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, but also potential upside from revenue growth and new product development.
• Employees: Continued investment in sales force and R&D may lead to growth opportunities, but also ongoing net losses and potential need for future financing.
• Customers (Healthcare Providers): Continued focus on improving diagnostic accuracy and timeliness of results for autoimmune diseases.
• Payors (Insurers): Ongoing efforts to demonstrate clinical utility and cost-effectiveness to secure reimbursement.
• Creditors: The company is in compliance with covenants under the Perceptive Term Loan Facility, but the loan is secured by substantially all company assets.

Next Steps

• Continue adoption of new biomarkers (T-Cell Biomarkers and RA Sub-Profile Biomarkers) to drive AVISE CTD ASP and gross margin.
• Pursue additional partnerships with pharmaceutical companies and academic research centers.
• Continue research and development for Lupus Nephritis (LN) biomarkers, SLE Disease Activity, RA Disease Activity, and Myositis Biomarkers.
• Seek broad coverage and reimbursement for testing products from third-party payors.
• Optimize revenue cycle management practices and focus managed care efforts on medical policy expansion.
• Continue to educate insurance payors on the clinical utility and cost-saving benefits of testing products.
• Potentially seek additional funding through equity offerings, debt financings, or other capital sources if needed.

Key Dates

Recommendation

The company shows positive revenue growth and improving ASP, indicating progress in its core business. However, the increasing net loss, significant decrease in cash reserves, and reliance on future financing and reimbursement approvals present considerable risks. The current situation warrants a 'hold' recommendation, pending clearer signs of a path to profitability and sustained cash flow generation.

Keywords

Exagen Inc., 10-Q, Quarterly Report, AVISE CTD, Autoimmune Disease Testing, Rheumatology, Medical Technology, Financial Results, Revenue Growth, Net Loss, Biomarkers, Perceptive Term Loan Facility